The company's consistent low ROCE and the increase in capital employed suggest that the business isn't deploying the funds into high return investments. This lackluster trend doesn't inspire confidence in the potential for the stock to be a multi-bagger.

Sichuan Hebang Biotechnology's low P/E ratio is due to its poor earnings performance and inconsistent growth. The market's annualised growth expectations for the company are unattractive, and investors see limited potential for earnings improvement.

The company's shift from loss to profit is viewed positively, likely boosting share prices. Despite recent downturns, long-term shareholders gained 8% annually over five years. If data suggests sustainable growth, the sell-off could be a worthy opportunity.